TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02395627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study: NCT02549053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophagus biopsies (pathologic and healthy zones)
Description: Biopsies were realised in the distal third of esophagus : 4 for Barrett esophagus patients (2 in healthy zone, 2 in pathological zone).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: esophagus biopsies (healthy zones)
Description: Biopsies were realised in the distal third of esophagus :2 for control patients in healthy zone
Study: NCT03886766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hot-melt extruded amorphous solid dispersion of Efavirenz homogenized to drug rich particles
Description: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hot-melt extruded amorphous solid dispersion of Efavirenz homogenized to drug rich particles
Description: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)
Study: NCT04033198

Intervention type: PROCEDURE
Intervention: Appendectomy
Description: patients diagnosed as acute appendicitis , appendectomy done

Intervention type: PROCEDURE
Intervention: Appendectomy
Description: patients diagnosed as acute appendicitis , appendectomy done
Study: NCT03886766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hot-melt extruded amorphous solid dispersion of Efavirenz homogenized to drug rich particles
Description: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz solution
Description: Efavirenz solution, 3 mg, oral administration (product 3)
Study: NCT01323660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/GW642444 62.5/25
Description: 62.5mcg/25mcg QID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK573719/GW642444 62.5/25
Description: 62.5mcg/25mcg QID
Study: NCT01086423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib™
Description: Intramuscular, three doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib™
Description: Intramuscular, three doses
Study: NCT03886766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz solution
Description: Efavirenz solution, 3 mg, oral administration (product 3)
Study: NCT01323660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 125
Description: 125mcg QID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK573719 125
Description: 125mcg QID
Study: NCT02229968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amicar (ε-aminocaproic acid)
Study: NCT01086423

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix Hib™
Description: Intramuscular, three doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Poliorix™
Description: Intramuscular, three doses
Study: NCT01517867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chicago Parent Program
Description: The Chicago Parent Program is a 12-session group-based parenting skills intervention for parents of young children with behavior problems

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent-Child Interaction Therapy
Description: Parent-Child Interaction Therapy is an individually-tailored coaching intervention for parents and young children with behavior problems
Study: NCT02229968

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study: NCT01323660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 62.5
Description: 62.5mcg QID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK573719 62.5
Description: 62.5mcg QID
Study: NCT02517866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil
Description: Azilsartan medoxomil tablets
Study: NCT03204461

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test (OGTT)
Description: For the assessment of glucose metabolism, including beta-cell function and insulin sensitivity an 75g-OGTT was conducted.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test (OGTT)
Description: For the assessment of glucose metabolism, including beta-cell function and insulin sensitivity an 75g-OGTT was conducted.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test (OGTT)
Description: For the assessment of glucose metabolism, including beta-cell function and insulin sensitivity an 75g-OGTT was conducted.

Intervention type: OTHER
Intervention: 1H-magnetic resonance spectroscopy
Description: The amount of ectopic lipids in the liver, heart and the skeletal muscle was measured using 1H-magnetic resonance spectroscopy.

Intervention type: OTHER
Intervention: 1H-magnetic resonance spectroscopy
Description: The amount of ectopic lipids in the liver, heart and the skeletal muscle was measured using 1H-magnetic resonance spectroscopy.

Intervention type: OTHER
Intervention: 1H-magnetic resonance spectroscopy
Description: The amount of ectopic lipids in the liver, heart and the skeletal muscle was measured using 1H-magnetic resonance spectroscopy.
Study: NCT01323660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 25
Description: 25mcg QID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 25
Description: 25mcg QID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW642444 25
Description: 25mcg QID

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo
Description: Comparator QID

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo
Description: Comparator QID

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo
Description: Comparator QID

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo
Description: Comparator QID

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo
Description: Comparator QID
Study: NCT01598025

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation (TBI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study: NCT03736694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia
Description: CBTI involves habitual, belief and attitude alterations so as to eliminate factors preventing sleep (Morin, Savard, Ouellet, \& Daley, 2003). It is recommended by the American College of Physicians as the first-line therapy for insomnia (Qaseem, Kansagara, Forciea, Cooke, \& Denberg, 2016). CBTI workshops are a relatively novel and emerging way of delivery which involves a greater number of patients than group CBTI, increases availability and accessibility by concentrating the content into half or whole day and taking place in the community settings, and reduces diagnostic labeling and cost (Bonin, Beecham, Swift, Raikundalia, \& Brown, 2014; Swift, Stewart, Andiappan, Smith, Espie, \& Brown, 2012). Self-help CBTI involves independent learning of the provided materials via the Internet, video or audio recording, books and pamphlets (Bruin, Bogels, Oort, \& Meijer, 2015).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia
Description: CBTI involves habitual, belief and attitude alterations so as to eliminate factors preventing sleep (Morin, Savard, Ouellet, \& Daley, 2003). It is recommended by the American College of Physicians as the first-line therapy for insomnia (Qaseem, Kansagara, Forciea, Cooke, \& Denberg, 2016). CBTI workshops are a relatively novel and emerging way of delivery which involves a greater number of patients than group CBTI, increases availability and accessibility by concentrating the content into half or whole day and taking place in the community settings, and reduces diagnostic labeling and cost (Bonin, Beecham, Swift, Raikundalia, \& Brown, 2014; Swift, Stewart, Andiappan, Smith, Espie, \& Brown, 2012). Self-help CBTI involves independent learning of the provided materials via the Internet, video or audio recording, books and pamphlets (Bruin, Bogels, Oort, \& Meijer, 2015).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene education
Description: SHE, is commonly provided verbally or through leaflets during consultations (Espie, 2009), and is also included as a part of CBTI (Morin, Savard, Ouellet, \& Daley, 2003).
Study: NCT02395627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study: NCT03241056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Maladaptive Beliefs about Memory
Description: The novel intervention is a manualized 2-session cognitive behavioural therapy. Agenda elements, including psycho-education, discussion prompts, and homework exercises are standardized across participants. In session 1, participants are taught about the cognitive theory of checking, the research support behind this theory, and how it may apply to their own checking behavior. A homework exercise is introduced and practiced to test out this theory. In session 2, the homework results are reviewed. Further education is shared on the nature of memory and the relationship to checking, and a discussion regarding how this applies to the participant's checking then takes place. A second homework exercise is introduced to test this theory.
Study: NCT02276404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation training
Description: The relaxation sessions comprise an introduction in 3 relaxation techniques conducted by a mind-body therapist: Body Scan, mindfulness meditation and imagination. Patients also receive a CD with different relaxation exercises and the instruction to exercise daily at home for at least 15 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation training
Description: The relaxation sessions comprise an introduction in 3 relaxation techniques conducted by a mind-body therapist: Body Scan, mindfulness meditation and imagination. Patients also receive a CD with different relaxation exercises and the instruction to exercise daily at home for at least 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The acupuncture treatment comprises needling of 6 standardized acupoints: Pericardium 6, Stomach 36, Large intestine 4, Spleen/Pancreas 10, Dumai 20, Liver 3, Shenmen. Additional points can be chosen individual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The acupuncture treatment comprises needling of 6 standardized acupoints: Pericardium 6, Stomach 36, Large intestine 4, Spleen/Pancreas 10, Dumai 20, Liver 3, Shenmen. Additional points can be chosen individual.
Study: NCT02163980

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caudal ropivacaine + normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caudal ropivacaine + dexmedetomidine
Study: NCT02439879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha lipoic acid
Description: Alpha lipoic acid 1800 mg PO divided in 3 doses for 4 weeks . If total symptoms score decreased \>3 points patients received alpha lipoic acid 600 mg PO each day or no treatment for 16 weeks.
Study: NCT03935412

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane Block

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane Block
Study: NCT02140112

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trichuris suis ova

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03263585

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal orthosis Spinomed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Equipment training
Study: NCT05191654

Intervention type: DIAGNOSTIC_TEST
Intervention: evaluation of cardiopulmonary parameters, gross motor development and hand grip strength
Description: Gross motor development was evaluated with Gross Motor Function Measure (GMFM-88). Hand grip strength was measured with the Baseline Pneumatic Bulb Dynamometer. Cardiopulmonary parameters values was evaluated with echocardiography.
Study: NCT02261610

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Procalcitonin algorithm
Description: Procalcitonin algorithm (usually used for lower respiratory tract) guide antibiotic therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procalcitonin algorithm
Description: Procalcitonin algorithm (usually used for lower respiratory tract) guide antibiotic therapy
Study: NCT06351371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study: NCT01417936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004
Description: Sym004 will be administered at the dose of 12 milligram per kilogram (mg/kg) as an intravenous infusion every week up to disease progression or withdrawal from treatment.
Study: NCT02407418

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manipulation
Description: Side-posture, high-velocity low-amplitude spinal manipulation targeting the lumbar spine and sacroiliac joints
Study: NCT03241056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual (TAU) during patients' time on our waitlist in our clinic will depend on at what point they have been recruited. It may consist of a 2-session group psychoeducational intervention on anxiety, any medications prescribed by their referring physicians, and/or independent therapy/counseling they may be seeking on the side. TAU for community participants will include any treatments they are currently seeking. Information about participation in such interventions will be collected during the course of the study (at each assessment visit) in order to accurately characterize participants' TAU in the current study.
Study: NCT06351371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT02407418

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Manipulation
Description: A simulated lumbar spine manipulation in which no vertebral contact was made
Study: NCT01368432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10 mg or 20 mg daily for 12 weeks by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill placebo
Study: NCT01270542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin (bevacizumab)
Description: single 0.05 mL intravitreal injection of bevacizumab 1.25 mg

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Subject's eyes will be anesthetized but no injection will be performed.
Study: NCT00810524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine
Description: 100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine
Description: 100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Study: NCT06004934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avacopan
Description: Administered orally.
Study: NCT01620281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: no!no!Back
Description: Self treatments daily for 3 weeks, in up to three 10-minutes sessions

Intervention type: DEVICE
Group type: OTHER
Intervention: no!no!Back
Description: Self treatments daily for 3 weeks, in up to three 10-minutes sessions
Study: NCT00438659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate
Description: Applied to treatment area

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Applied to treatment area
Study: NCT02987634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PeriActive
Description: mouthwash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PeriActive
Description: mouthwash
Study: NCT01022255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous FL vaccine
Description: 1.0 mg of vaccine subcutaneously (s.c.) on Day 1, and followed by 125 µg GM-CSF s.c. at Day 1 -4, monthly until 8th vaccination, bimonthly until 12th vaccination (month 16)
Study: NCT00810524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine
Description: 100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine
Description: 100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: 600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine
Description: 600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: 600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine
Description: 600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enticavir
Description: 0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enticavir
Description: 0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
Study: NCT06351371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT00810524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enticavir
Description: 0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enticavir
Description: 0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir Dipivoxil Tablets
Description: 10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir Dipivoxil Tablets
Description: 10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir Dipivoxil Tablets
Description: 10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir Dipivoxil Tablets
Description: 10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Study: NCT00535366

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium
Description: Oral inhalation by HandiHaler® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Oral inhalation by HandiHaler® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Oral inhalation by HandiHaler® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Oral inhalation by HandiHaler® device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salmeterol
Description: Oral inhalation from Diskus®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Oral inhalation from Diskus®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Oral inhalation from Diskus®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Oral inhalation from Diskus®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Oral inhalation from metered dose inhaler (MDI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide low
Description: Oral inhalation from MDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide high
Description: Oral inhalation from MDI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral inhalation from MDI
Study: NCT01598025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study: NCT04462510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Block/Local infiltration
Description: One group received ILI/IHG Block and the other group received local anesthetic infiltration for pain relief

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Block/Local infiltration
Description: One group received ILI/IHG Block and the other group received local anesthetic infiltration for pain relief
Study: NCT01598025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT04210583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vulvovaginal Treatment
Description: Device model(s) - Venus Fiore™ Device settings and programming internal applicator - 42°C - 45°C Temperature output via automatic temperature control (ATC) (optional treatment).~Duration of exposure and frequency of exposure with internal applicator - one treatment for 12-15 minutes at 12 months (optional treatment).~Device settings and programming external mons pubis and labia applicators - 10-35% output (optional treatment).~Duration of exposure and frequency of exposure external applicators - one treament for 15 minutes for the mons pubis, 10 minutes for labia at 12 months (optional treatment).